RCC Treatment Strategies in a Favorable-Risk Patient - a podcast by ReachMD

CME credits: 0.50

Valid until: 17-09-2022

Claim your CME credit at https://reachmd.com/programs/cme/rcc-treatment-strategies-in-a-favorable-risk-patient/12798/

Immune checkpoint inhibitor/tyrosine kinase inhibitor combination therapy has forged to the front-line for the management of metastatic RCC and recurrent RCC, but how do clinicians select the ideal treatment regimen for their patients? How does patient risk status influence the decision-making process? This virtual tumor board features a multidisciplinary expert panel presenting a favorable-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize outcomes in this patient population. Faculty additionally cover the importance of incorporating the patient perspective into treatment decisions.

After viewing the activity, visit the Related tab for supplemental resources.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD